Glucagon-like Peptide-1 Retards Gastric Emptying and Small Bowel Transit in the Rat (Effect Mediated Through Central or Enteric Nervous Mechanisms)

[1]  J. Holst,et al.  Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man , 1993, Digestive Diseases and Sciences.

[2]  J. Holst,et al.  Pancreatic and intestinal processing of proglucagon in man , 1987, Diabetologia.

[3]  S. Davis,et al.  Hypoglycemia associated autonomic failure , 2002, Clinical Autonomic Research.

[4]  J. Holst,et al.  Glucagon-Like Peptide I Enhances the Insulinotropic Effect of Glibenclamide in NIDDM Patients and in the Perfused Rat Pancreas , 1996, Diabetes Care.

[5]  J. Holst,et al.  Glucagon-Like Peptide I Receptors in the Subfornical Organ and the Area Postrema Are Accessible to Circulating Glucagon-Like Peptide I , 1996, Diabetes.

[6]  J. Holst,et al.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[7]  S. Mojsov,et al.  Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequences , 1995, FEBS letters.

[8]  T. Onuma,et al.  Altered Postprandial Insulin Requirement in IDDM Patients With Gastroparesis , 1994, Diabetes Care.

[9]  John R. Christiansen,et al.  Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. , 1994, Scandinavian journal of gastroenterology.

[10]  J. Holst,et al.  Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.

[11]  M. Wheeler,et al.  Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. , 1993, Endocrinology.

[12]  J. Dent,et al.  Disordered gastric emptying: mechanical basis, assessment and treatment. , 1991, Bailliere's clinical gastroenterology.

[13]  G. Weir,et al.  Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3',5'-monophosphate formation. , 1990, Endocrinology.

[14]  M. Gregor,et al.  The role of gut-glucagon-like immunoreactants in the control of gastrointestinal epithelial cell renewal. , 1990, Digestion.

[15]  W. Fujimoto,et al.  Effects of Glucagonlike Peptide l-(7–36) on Release of Insulin, Glucagon, and Somatostatin by Rat Pancreatic Islet Cell Monolayer Cultures , 1989, Diabetes.

[16]  P. Hellström,et al.  Neuropeptide Y Inhibits the Migrating Myoelectric Complex and Delays Small Intestinal Transit in Rats , 1989 .

[17]  M. Namba,et al.  Glucagonostatic and Insulinotropic Action of Glucagonlike Peptide I-(7–36)-Amide , 1989, Diabetes.

[18]  J. Holst,et al.  Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. , 1988, Endocrinology.

[19]  K. Shima,et al.  Effect of glucagon-like peptide-1 on insulin secretion , 1988, Regulatory Peptides.

[20]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[21]  I. Goldfine,et al.  Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans. , 1987, The Journal of clinical endocrinology and metabolism.

[22]  G. Weir,et al.  Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. , 1987, The Journal of clinical investigation.

[23]  J. Holst,et al.  Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut , 1987, FEBS letters.

[24]  J. Holst,et al.  Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. , 1986, Endocrinology.

[25]  L. Orci,et al.  Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. , 1986, The Journal of biological chemistry.

[26]  P. Hellström,et al.  Effects of neurotensin on the transit of gastrointestinal contents in the rat. , 1982, Acta physiologica Scandinavica.

[27]  S. Efendić,et al.  Effects of cholecystokinin, gastric inhibitory polypeptide, and secretin on insulin and glucagon secretion in rats. , 1982, Endocrinology.

[28]  T. Burks,et al.  Accurate measurement of intestinal transit in the rat. , 1981, Journal of pharmacological methods.

[29]  K. Kelly,et al.  Inhibition of canine interdigestive proximal gastric motility by cholecystokinin octapeptide. , 1981, The American journal of physiology.

[30]  T. Schwartz,et al.  Impaired response of pancreatic polypeptide to hypoglycaemia: an early sign of autonomic neuropathy in diabetics. , 1979, British medical journal.

[31]  L. Buéno,et al.  Insulin and jejunal electrical activity in dogs and sheep. , 1976, The American journal of physiology.

[32]  J. Brown,et al.  Identification and actions of gastric inhibitory polypeptide. , 1975, Recent progress in hormone research.

[33]  M. Hjelm,et al.  A METHODOLOGICAL STUDY OF THE ENZYMATIC DETERMINATION OF GLUCOSE IN BLOOD. , 1963, Scandinavian journal of clinical and laboratory investigation.